|
Age (years)
|
65.09 ± 12.65
|
63.86 ± 14.33
|
0.824
|
|
Gender, male (%)
|
5 (45.46)
|
5 (35.71)
|
0.622
|
|
Prior hospital stay (<1 year)
|
3 (27.27)
|
2 (14.29)
|
0.420
|
|
Length of stay in ICU (days)
|
6 (3–25)
|
11 (2.75–25.75)
|
0.784
|
|
APACHE II score upon ICU admission
|
21.82 ± 7.13
|
21.50 ± 8.04
|
0.919
|
|
SOFA score upon ICU admission
|
6.55 ± 3.14
|
7.00 ± 6.49
|
0.762
|
|
Primary ICU admission diagnosis
| | | |
|
Chronic pulmonary disease
|
8 (72.72)
|
4 (28.57)
|
0.028
|
|
Pneumonia
|
8 (72.72)
|
8 (57.14)
|
0.42
|
|
Diabetes mellitus
|
1 (9.09)
|
2 (14.28)
|
0.692
|
|
Hypertension
|
2 (18.18)
|
5 (35.71)
|
0.332
|
|
Malignancy
|
2 (18.18)
|
3 (21.42)
|
0.84
|
|
Surgery procedure (<30 days)
|
1 (9.09)
|
5 (35.71)
|
0.122
|
|
Antibiotic classesb
| | | |
|
Carbapenem
|
7 (63.63)
|
6 (42.86)
|
0.302
|
|
Penicillins
|
3 (27.27)
|
6 (42.56)
|
0.420
|
|
Piperacillin/tazobactam
|
5 (45.45)
|
6 (42.86)
|
0.897
|
|
Cefepime
|
7 (63.63)
|
6 (42.86)
|
0.302
|
|
Fluoroquinolones
|
3 (27.28)
|
3 (21.42)
|
0.734
|
|
Glycopeptide
|
6 (54.54)
|
8 (57.14)
|
0.716
|
|
Antifungal
|
4 (36.36)
|
4 (28.57)
|
0.678
|
|
ICU procedures
| | | |
|
Ventilator
|
11 (100)
|
14 (100)
|
--
|
|
Blood transfusion
|
5 (45.45)
|
7 (50)
|
0.821
|
|
Hemodialysis
|
0 (0)
|
4 (28.57)
|
0.053
|
|
Nasogastric tube
|
11 (100)
|
12 (85.71)
|
0.191
|
|
Venous central catheter
|
10 (81.82)
|
13 (92.86)
|
0.859
|
|
Peripheral venous catheter
|
11 (100)
|
13 (92.86)
|
0.366
|
|
Arterial catheter
|
4 (36.36)
|
6 (42.86)
|
0.742
|
|
Urinary catheter
|
11 (100)
|
14 (100)
|
--
|
|
Outcome
| | | |
|
28-day mortality
|
3 (27.27)
|
2 (14.29)
|
0.420
|
|
Hospital mortality
|
6 (54.56)
|
3 (21.42)
|
0.032
|
